Huadong Medicine Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Huadong Medicine Stock Forecast and Price Target
The average price target for Huadong Medicine's stock of ¥46.59 recently provided by three leading analysts would represent a 42.26% upside from its last closing price if reached. This potential increase is based on a high estimate of ¥62.00 and a low estimate of ¥40.00. Even if you're not interested in 000963 stock, you may be interested in its competitors.
42.26% Upside
Huadong Medicine Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Huadong Medicine's Price has decreased by 100.00%, from ¥24.52 to ¥0.00. For next year, analysts predict Fair Value of ¥36.16, which would mean an increase of 100.00%. Over the next seven years, experts predict that Huadong Medicine's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.29 | Buy/Sell | $178.42 | 12.98% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF218.80 | Buy/Sell | CHF307.83 | 24.54% |
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.52k | Buy/Sell | Rp1.52k | 4.27% |
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF513.80 | Buy/Sell | CHF516.89 | 13.86% |
Huadong Medicine Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Huadong Medicine's Revenue has grown by 20.61%, rising from ¥33.68B to ¥40.62B. For the next year, 0 analysts project Huadong Medicine's Revenue to drop by 6.02%, reaching ¥38.18B. By 2030, professionals believe that Huadong Medicine's Revenue will decrease by 7.18%, reaching ¥37.71B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.46k | Buy/Sell | ¥2.64k | 39.18% |
| 603259 Stock Forecast | WuXi AppTec | Buy |
18
|
¥41.60 | Buy/Sell | ¥121.48 | 61.71% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.25 | Buy/Sell | $11.59 | 20.75% |
.jpg)
Huadong Medicine Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Huadong Medicine's Dividend per Share has grown by 152.17%, rising from ¥0.23 to ¥0.58. According to 10 prominent analysts, Huadong Medicine's Dividend per Share will fall by 24.14% in the next year, reaching ¥0.44. Over the next seven years, experts predict that Huadong Medicine's Dividend per Share will grow at a rate of 13.61%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp6.22k | Buy/Sell | Rp5.67k | -2.69% |
| 601607 Stock Forecast | Shanghai Pharmaceuticals Holdi... | Outperform |
18
|
¥17.81 | Buy/Sell | ¥20.67 | 23.53% |
| 600998 Stock Forecast | Jointown Pharmaceutical Group | Outperform |
18
|
¥8.21 | Buy/Sell | ¥7.70 | 33.98% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| 603707 Stock Forecast | Nanjing King-Friend Biochemica... | Buy |
16
|
¥13.91 | Buy/Sell | ¥20.19 | 45.15% |
| 603456 Stock Forecast | Zhejiang Jiuzhou Pharmaceutica... | Buy |
18
|
¥15.11 | Buy/Sell | ¥37.79 | 56.25% |
Huadong Medicine EBITDA Forecast for 2023 - 2025 - 2030
Huadong Medicine's EBITDA has grown In the last three years, rising from ¥3.45B to ¥4.30B – a growth of 24.87%. In the next year, analysts believe that EBITDA will reach ¥5.23B – an increase of 21.44%. For the next seven years, experts predict that Huadong Medicine's EBITDA will grow at a rate of 90.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 512 Stock Forecast | Grand Pharmaceutical Group | Buy |
18
|
HK$4.26 | Buy/Sell | HK$7.60 | -100.00% |
| 000950 Stock Forecast | C.Q. Pharmaceutical Holding | Buy |
14
|
¥5.37 | Buy/Sell | ¥0.00 | -100.00% |
| STAR Stock Forecast | Strides Pharma Science | Outperform |
9
|
Rp883.45 | Buy/Sell | Rp618.00 | -6.79% |
Huadong Medicine EBIT Forecast for 2023 - 2025 - 2030
Huadong Medicine's EBIT has seen impressive growth In the last three years, rising from ¥3.02B to ¥3.59B – a growth of 18.73%. In the next year, analysts believe that EBIT will reach ¥4.44B – an increase of 23.56%. For the next seven years, the forecast is for EBIT to grow by 93.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600713 Stock Forecast | NanJing Pharmaceutical Company | - |
16
|
¥4.72 | Buy/Sell | ¥11.60 | -100.00% |
| 1762 Stock Forecast | Chunghwa Chemical Synthesis & ... | Hold |
16
|
NT$44.90 | Buy/Sell | NT$70.00 | 6.90% |
| CLGN Stock Forecast | CollPlant Biotechnologies | Buy |
7
|
$5.55 | Buy/Sell | $0.00 | 204.14% |
Huadong Medicine EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Huadong Medicine's EPS has decreased by 100.00%, from ¥1.39 to ¥0.00. For next year, analysts predict EPS of ¥2.05, which would mean an increase of 100.00%. Over the next seven years, experts predict that Huadong Medicine's EPS will grow at a rate of 100.00%.
.jpg)